Dosing Cariprazine Within and Beyond Clinical Trials

Recommendations for the Treatment of Schizophrenia

Bibliographic Data

ID15528541
AuthorsElmārs Rancāns (0000-0002-8329-7887, Riga Stradiņš University, corresponding author), Z B Dombi (0000-0002-0390-4852, University of Oxford), Ágota Barabássy (Gedeon Richter (Hungary))
Year2022
Volume12
Pages770234-770234
Publication date2022-01-05
Peer ReviewedYes
Open AccessYes
TypeARTICLE
VenueFrontiers in Psychiatry (JOURNAL)
Journal identifiersISSN: 1664-0640 • E-ISSN: 1664-0640
PublisherFrontiers Media (PUBLISHER • CH)
DOI10.3389/fpsyt.2021.770234
PMID35069278
OpenAlexW4205194633
LanguageEN
Citations received7
References cited42

Although the optimal dosing of an antipsychotic medication is known to be essential in the long-term management of schizophrenia, in case of novel drugs such as cariprazine, determining the right dosing strategy is not that simple. Without decades of experience with a particular compound, evidence regarding dosing and titration comes primarily from double-blind, placebo controlled clinical trials that are not necessarily mirroring the real-life experiences of doctors. Via summarizing data from both clinical data ( n = 3275) and real-world evidence (observational study n = 116, case studies n = 29), this perspective paper aims to shed a light on the appropriate dosing strategies of cariprazine from treatment initiation through switching strategies to concomitant medications

Clinical trial · Dosing · Intensive care medicine · Mirroring · Observational study · Psychiatry · Schizophrenia (object-oriented programming · Health Systems, Economic Evaluations, Quality of Life · Medicine · Mental Health Research Topics · Psychology · Schizophrenia research and treatment · Internal Medicine · Pharmacology

Tools

Open DOIOpen Access